Comparison of costs and utilization among buprenorphine and methadone patients

Addiction

Volumn 104, Issue 6, 2009, Pages 982-992

  Barnett, Paul G ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Buprenorphine; Cost and cost analysis; Economics; Health care cost; Methadone; Opioid related disorders rehabilitation; Substance abuse treatment; Veterans

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; AMBULATORY CARE; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; OPIATE ADDICTION; PATIENT COMPLIANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUPRENORPHINE; DRUG UTILIZATION; HEALTH CARE COSTS; HUMANS; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; YOUNG ADULT;

EID: 65549091945     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02539.x     Document Type: Article

References (23)

1. NIH Consensus Conference. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998 280 : 1936 43.
2. Joseph H., Stancliff S., Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000 67 : 347 64.
3. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004 3. CD002207.
4. Sullivan L. E., Fiellin D. A. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005 41 : 891 6. (Pubitemid 41266759)
5. Sullivan L. E., Moore B. A., Chawarski M. C., Pantalon M. V., Barry D., O'Connor P. G. et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2007 35 : 87 92.
6. Schackman B. R., Merrill J. O., McCarty D., Levi J., Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006 43 : S247 53.
7. Donaher P. A., Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician 2006 73 : 1573 8. (Pubitemid 43807052)
8. Rosenheck R., Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001 63 : 253 62. (Pubitemid 32545411)
9. Doran C. M., Shanahan M., Mattick R. P., Ali R., White J., Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003 71 : 295 302. (Pubitemid 38368580)
10. Harris A. H., Gospodarevskaya E., Ritter A. J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005 23 : 77 91. (Pubitemid 40194011)
11. Harris A. VA Care for Substance Use Disorder Patients: Indicators of Facility and VISN Performance (Fiscal Years 2004 and 2005). Palo Alto, CA : VA Program Evaluation Research Center and HS&RD Center for Health Care Evaluation 2006.
12. Gordon A. J., Trafton J. A., Saxon A. J., Gifford A. L., Goodman F., Calabrese V. S. et al. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend 2007 90 : 292 6. (Pubitemid 47299171)
13. Barnett P. G., Rodgers J. H. Use of the decision support system for VA cost-effectiveness research. Med Care 1999 37 : AS63 70.
14. Yu W., Ravelo A., Wagner T. H., Bhandari A., Phibbs C. S., Barnett P. G. The cost of care for chronic diseases in the VA. Med Care Res Rev 2003 60 : 146S 167S.
15. US Centers for Medicare and Medicaid Services. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2006 rates. Final rule. Fed Regist 2005 70 : 47277 707.
16. Manning W. G., Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001 20 : 461 94. (Pubitemid 32515166)
17. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R. et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007 102 : 1899 907. (Pubitemid 350145664)
18. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007 11 : 1 171, iii iv. (Pubitemid 47207726)
19. Zarkin G. A., Dunlap L. J., Homsi G. The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services cost. Eval Program Plann 2004 23 : 35 43. (Pubitemid 37551534)
20. Sales M. M., Cunningham F. E., Glassman P. A., Valentino M. A., Good C. B. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manag Care 2005 11 : 104 12. (Pubitemid 40250538)
21. Gourevitch M. N., Chatterji P., Deb N., Schoenbaum E. E., Turner B. J. On-site medical care in methadone maintenance: associations with health care use and expenditures. J Subst Abuse Treat 2007 32 : 143 51. (Pubitemid 46240719)
22. Barnett P. G., Rodgers J. H., Bloch D. A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001 96 : 683 90. (Pubitemid 32458706)
23. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Treatment Improvement Protocol (TIP) Series 40. Rockville, MD : Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment 2004.